Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Nasdaq

The Final Call: Time To Buy These Undervalued Stocks

On CNBC's "The Final Call," Carter Worth named Intuit Inc. (NASDAQ: INTU). Shares of the company have lost more than 40% year to date.

Benzinga

Ryanair FY22 Loss Narrows, Expects To Return To Profitability In FY23

Ryanair Holdings plc (NASDAQ:RYAAY) reported FY22 revenue growth of 193% year-over-year to €4.8 billion. The company reported an FY22 net loss of €(355) million, compared to a €(1.05) billion loss a year ago. Scheduled revenues were up 156% Y/Y, reflecting a rise in traffic from 27.5 million customers to 97.1 million. Ancillary…

Benzinga

5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Wedbush Upgrades Netflix As 'Immensely Profitable, Slow-Growth Company': What Else Interests The Analyst?

Netflix Inc (NASDAQ: NFLX) shares traded higher by 3.3% on Monday after the company received an upgrade on Wall Street. The Analyst: Wedbush analyst Michael Pachter upgraded Netflix from Neutral to Outperform and reiterated his $280 price target.

Benzinga

Earnings Preview For Kamada

Kamada (NASDAQ:KMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that Kamada will report an earnings per share (EPS) of $0.02.

Benzinga

Expert Ratings for Akebia Therapeutics

Over the past 3 months, 4 analysts have published their opinion on Akebia Therapeutics (NASDAQ:AKBA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

CrowdStrike Holdings Whale Trades For May 16

A whale with a lot of money to spend has taken a noticeably bullish stance on CrowdStrike Holdings. Looking at options history for CrowdStrike Holdings (NASDAQ:CRWD) we detected 14 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Preview: MediWound's Earnings

MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that MediWound will report an earnings per share (EPS) of $-0.11.

Benzinga

Earnings Preview: ObsEva

ObsEva (NASDAQ:OBSV) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that ObsEva will report an earnings per share (EPS) of $-0.20.

Benzinga

Expert Ratings for Sterling Check

Over the past 3 months, 7 analysts have published their opinion on Sterling Check (NASDAQ:STER) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Earnings Preview: Edap TMS

Edap TMS (NASDAQ:EDAP) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that Edap TMS will report an earnings per share (EPS) of $-0.03.

Benzinga

Earnings Outlook For NextGen Healthcare

NextGen Healthcare (NASDAQ:NXGN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that NextGen Healthcare will report an earnings per share (EPS) of $0.19.

Benzinga

Expert Ratings for Atlassian Corporation

Atlassian Corporation (NASDAQ:TEAM) has observed the following analyst ratings within the last quarter:

Benzinga

Why Bitcoin-, Ethereum- And Litecoin-Related Stock Bitfarms Is Diving Today

Bitfarms Ltd (NASDAQ: BITF) shares are trading lower by 7.00% at $1.89. The company reported first-quarter earnings results Monday morning.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What 4 Analyst Ratings Have To Say About Velodyne Lidar

Velodyne Lidar (NASDAQ:VLDR) has observed the following analyst ratings within the last quarter:

Benzinga

Flora Growth Appoints Cannabis Regulatory Veteran Holly Bell As VP Of Regulatory Affairs

Flora Growth Corp. (NASDAQ: FLGC) appointed regulatory veteran Holly Bell as vice president of regulatory affairs. Bell will play a critical role in Flora’s domestic and global expansion strategy and lead government relations in key international markets.

Benzinga

Golden Cross Appears Before argenx Investors

If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

POET: Could POET's Biggest Market Be AI Accelerators?

By Lisa Thompson NASDAQ:POET READ THE FULL POET RESEARCH REPORT

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

5 Value Stocks In The Communication Services Sector

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga

5 Value Stocks In The Healthcare Sector

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga

FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review

The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of IgA nephropathy (IgAN).

Benzinga

Insider Buying Remains Elevated For A Second Week $SBUX $UBER $RILY

In an unusually volatile week, we saw significant market weakness earlier in the week probably driven by forced selling and a relief rally in the end. Insiders once again stepped up their purchases to take advantage of prices, which in some cases are down anywhere from 50% to 90% from…

Benzinga

NVIDIA Whale Trades For May 16

Someone with a lot of money to spend has taken a bullish stance on NVIDIA (NASDAQ:NVDA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

GT Biopharma: Q1 Earnings Insights

GT Biopharma (NASDAQ:GTBP) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Recap: Aprea Therapeutics Q1 Earnings

Aprea Therapeutics (NASDAQ:APRE) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

1 … 475 476 477 478

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Walgreens Boots Alliance

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.